Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Barrett Esophagus
Research from H. Vandekken et al broadens understanding of barrett esophagus
December 9th, 2008
According to a study from Netherlands, "Histopathologic grading of dysplasia in Barrett esophagus (BE) shows substantial interobserver and intraobserver variation. We used immunohistochemical analysis with a set of tumor cell markers, ie, epidermal growth factor receptor (EGFR), ERBB2 (HER2/neu), MYC, CDKN2A (p16), SMAD4, MET, CCND1 (cyclin D1), CTNNB1 (beta-catenin), and TP53 (p53), in histologic sections of endoscopic biopsies of 86 patients with BE in various stages of neoplastic progression." "The markers, except SAMD4, were scored as 0 (< 1% of cells stained), 1 (1%-25%), 2 (26%-50%), or 3 (> 50%). All markers, except EGFR, showed a significant trend for...
Source: Cancer Weekly (2008-12-09)
|
